TransMedics Group, Inc. Earnings Recaps
Q3 2025
Oct 31, 2025
TransMedics achieved robust Q3 2025 results, with total revenue up 32.2% year-over-year to approximately $144 million, driven by strong growth across all organ segments despite typical seasonal slowdowns.
Key takeaways
- Operating profit soared to $23.3 million, representing over 16% of total revenue, compared to just 4% in Q3 2024.
- Transplant logistics service revenue grew 35% year-over-year, with 21 aircraft currently operational to enhance mission coverage.
- Anticipation builds for the upcoming ENHANCE Heart and DENOVO Lung clinical trials, expected to drive future adoption of OCS technology.
- Expansion into international markets is underway, with plans to launch the first OUS NOP program in Italy and establish strategic regional hubs.